Regeneron Pharmaceuticals, Inc. (REGN)
After hours:
| Previous close | 1,014.59 |
| Open | 1,015.40 |
| Bid | 1,011.67 x 100 |
| Ask | 1,012.74 x 100 |
| Day's range | 1,007.28 - 1,023.09 |
| 52-week range | 769.19 - 1,211.20 |
| Volume | |
| Avg. volume | 519,756 |
| Market cap | 111.648B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | 26.81 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Regeneron Pharmaceuticals, Inc. (REGN): A Buzzing AI Health Stock to Add to Your Portfolio
We recently compiled a list of the 10 Buzzing AI Health Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other buzzing AI health stocks. The economic impact of AI is projected to be substantial, particularly in regions like China and North America, which are […]
- Zacks
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
- Insider Monkey
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
We recently compiled a list of the Cramer’s Morning Thoughts: 20 Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against the other stocks to watch according to Jim Cramer. In a recent episode of Mad Money, Jim Cramer explains that if you’re investing with […]
